Genetic Analysis: Sales down, margins up, China entry and capital raise position GA for future growth

About this update from Genetic Analysis As

Q1 2025 saw a 27% sales decline but improved gross margin and reduced losses, with strategic expansion into China and a NOK 12.8 million capital raise post-quarter to fund growth and product launches. Market trends remain favorable for future sales. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genetic Analysis As